Cue Biopharma, Inc. is a biotechnology company focused on developing precision immuno-engineered therapies for allergic and autoimmune diseases. Its lead product, CUE-221, is an anti-IgE antibody in Phase 2 development aimed at treating IgE-mediated allergic diseases. The company also utilizes its Immuno-STAT® platform to create therapies that selectively target disease-specific T cells for autoimmune conditions, with CUE-401, a bifunctional IL-2 and TGF-β program, advancing toward Phase 1 development. Cue Biopharma operates primarily in the United States.
- Website
- www.cuebiopharma.com
- Issuer profile
- All listings